hasta hace 2 tardes ella misma (como buena "feminista") nos contaba que el "jenaro" es un "konstrukto sozial" y que las mujeres tenían que penetrar analmente a los hombres:
La nueva Directora del Instituto de la Mujer: “Las feministas tienen que tener una agenda sexual radical”
probablemente más de una "feminista" se va a creer ésta nueva teoría, porque las mujeres no mienten (oficialmente te cuentan que las "denuncias falsas" representan algo menos del 0,000000000000000000000000000000000000000000000000000000000000000000000001% del total de denuncias, aunque todos los días se descubren denuncias falsas, y el 80% de denuncias no acaban en condena.. y eso que el hombre empieza el juicio siendo culpable "por el mero hecho de ser hombre").. y porque para saber lo que pasa realmente hay que tener un poco de cultura.. si te crees lo que te cuentan vas bien, pero bien..el próximo 8M veremos cuantas se creen el cuento..
resumen: no dejes que la realidad te estropee una bonita fantasía..
para el resto:
Gender differences in clinical registration trials: is there a real problem?
Aims
Several studies have reported the under‐representation of women in clinical trials, thereby challenging the external validity of the benefit/risk assessments of launched drugs. Our aim was to determine the extent to which women have been included in clinical trials used for drug registration and to analyse the fraction of women participating in phases I, II and III.
Methods
We conducted cross‐sectional, structured research into publicly available registration dossiers of Food and Drug Administration (FDA)‐approved drugs that are prescribed frequently. Furthermore, we analysed compounds with high hepatic clearance and a known gender‐related difference in drug response. In a sensitivity analysis, we compared figures with US disease prevalence data.
Results
For 38 of the initial 137 drugs (28%), sufficient data were reported and publicly available. For these drugs, 185 479 trial participants were included, of whom 47% were female and 44% were male; gender was not reported for 9% of participants. However, the number of female participants varied with the phase of the trial, with 22% females in phase I trials vs. 48% and 49%, respectively, in phase II and III trials. When compared with US disease prevalence data, 10 drugs (26%) had a greater than 20% difference between the proportion of females affected with the disease compared with representation in clinical trials.
Conclusions
From these publicly available data, there was no evidence of any systematic under‐representation of women in clinical trials.
mención aparte para el 22% de mujeres en la phase I (aunque la población que puede entender lo que eso significa no llegará al 5%).. éste es otro de los "pribilejios" de los hombres, como ir a primera linea de la guerra.. aunque ya sabemos que las mujeres siempre son las principales "biktimas":
#yotecreo
disfruten lo votado..
No hay comentarios:
Publicar un comentario